Home / Companies / Quality Drugs / Trends
Quality Drugs H-1B trends
Quarterly LCA aggregate trend points for Quality Drugs. Each point carries filing counts, distinct employers, distinct role titles, SOC coverage, wage metrics, certification counts, and source IDs when returned.
Summary
H-1B LCA filings for Quality Drugs span 2021 Q4 to 2023 Q4, peaking at 2 filings in 2023 Q4.
The most recent reported period (2023 Q4) shows 2 filings.
LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
| Period | LCA count | Role titles | SOC codes | Avg wage low | Avg prevailing | Certified | Certification rate |
|---|---|---|---|---|---|---|---|
| 2021 Q4 | 1 | 1 | 1 | $76,294 | $76,294 | 1 | 100.0% |
| 2023 Q4 | 2 | 1 | 1 | $33,280 | $33,280 | 2 | 100.0% |
Frequently asked questions
- How have H-1B filings for Quality Drugs changed over time?
- H-1B LCA filings for Quality Drugs span 2021 Q4 to 2023 Q4, peaking at 2 filings in 2023 Q4. The most recent reported period (2023 Q4) shows 2 filings. LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
Get this page with API
Rendered from the bluedoor H-1B Jobs API. Reproduce it:
GET https://api.bluedoor.sh/h1b-jobs/v1/trends?company=quality+drugs&metric=lca_countJSON